Option chain shows key data for Bluerock Homes Trust's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bluerock Homes Trust.

Bluerock Homes Trust (AMEX:BHM) Stock, Option Chain

Bluerock Homes Trust Inc owns and operates single-family properties that generate rental and other property-related income through the leasing of units to a diverse base of tenants. The properties are located in Sunbelt and the Western United States.

Real estate

REIT

Real Estate

Bluerock Homes Trust, Inc. Class A Common Stock

FCPT

5 REITs With Recent Insider Buying

Concept,Of,Several,Properties,In,A,City,Generating,Passive,Income

Short Sellers

Hannon Armstrong Sustainable Infrastructure Capital

HASI

STRW

3 Little-Known REITs Making Big Gains Lately

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

RMAX

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.

Top 5 Real Estate Stocks That May Explode In August

Bluerock Homes Trust Inc

BH MACRO LTD GBP by BH Macro, Ltd.

BH MACRO LTD USD by BH Macro, Ltd.

Piper Sandler analyst Alex Goldfarb maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Overweight and lowers the price target from $90 to $75.

Price Target

Analyst Ratings

LINE

Piper Sandler Maintains Overweight on Lineage, Lowers Price Target to $75

WIIM

QNRX

Quoin Pharmaceuticals shares are trading higher after the company announced its whole body data from ongoing pediatric netherton syndrome study.

Piper Sandler analyst Kashy Harrison maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Neutral and raises the price target from $119 to $124.

ITRI

Piper Sandler Maintains Neutral on Itron, Raises Price Target to $124

ALBERT G. LOWENTHAL TRANSITIONS TO EXECUTIVE CHAIRMAN
ROBERT S. LOWENTHAL APPOINTED CEO &amp; PRESIDENT
NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Oppenheimer Holdings Inc. today announced that Albert G. Lowenthal, Chairman of the Board of Directors and Chief Executive Officer (CEO), would step down as CEO of the Company and its primary operating subsidiary, Oppenheimer &amp; Co. Inc. (Opco), effective at the close of the Annual Shareholders Meeting of the Company to be held on May 5, 2025. Mr. Lowenthal will continue in his role as Chairman of the Company and also will serve as Executive Chairman of Opco. He will be succeeded by Robert S. Lowenthal, currently serving as President and Head of Investment Banking, who will become CEO and President.

Management

Oppenheimer Holdings Inc. Announces CEO Succession; Albert G. Lowenthal Transitions To Executive Chairman; Robert S. Lowenthal Appointed CEO & President

Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>, LUNRW))) ("Intuitive Machines") ("Company"), a leading space exploration, infrastructure, and services company, has announced its IM-2 mission Nova-C class lunar lander, Athena, launched on SpaceX's Falcon 9 rocket and successfully commissioned in space, marking the first time humanity has had three lunar landers en route to the Moon at the same time.
Athena established a stable attitude, solar charging, and radio communications contact with the Company's mission operations center in Houston after liftoff on February 26. The lander is in excellent health and preparing for a series of planned main engine firings to refine her trajectory ahead of lunar orbit insertion, which is planned for March 3. Intuitive Machines expects a lunar landing opportunity on March 6.

LUNR

Intuitive Machines' IM-2 Lunar Lander Successfully Commissioned And En Route To The Moon

HC Wainwright &amp; Co. analyst Kevin Dede reiterates MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Buy and maintains $28 price target.

Reiteration

MARA

HC Wainwright & Co. Reiterates Buy on MARA Holdings, Maintains $28 Price Target

VMAR

Vision Marine Technologies shares are trading higher after the company announced a three-year exclusive deal with STERK for electric boats.

Contracts

BKTI

BK Technologies Receives A Purchase Order From A State Forestry Agency For Its InteropONE Solution, Terms Not Disclosed

Standard Motor Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMP#NYSE">SMP</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.44 by 6.82 percent. This is a 27.03 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $343.40 million which beat the analyst consensus estimate of $300.89 million by 14.13 percent. This is a 18.11 percent increase over sales of $290.76 million the same period last year.

Earnings

Earnings Beats

Standard Motor Products Q4 2024 Adj EPS $0.47 Beats $0.44 Estimate, Sales $343.40M Beat $300.89M Estimate

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease
FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial of crofelemer in the prespecified subgroup of patients with breast cancer
Jaguar has received an indication of interest to acquire the Company
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / February 27, 2025 / <a href="https://pr.report/7peo">Jaguar Health, Inc.</a> <a href="https://pr.report/7pep">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or the "Company") today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan").

JAGX

Jaguar Health Adopts Limited Duration Stockholder Rights Plan To Ensure Stockholders Can Realize Long-Term Value; Jaguar Has Received An Indication Of Interest To Acquire The Company

Pennsylvania is edging closer to full cannabis legalization, with <a href="https://www.senatorlaughlin.com/2025/02/25/laughlin-introduces-bipartisan-plan-to-legalize-adult-use-marijuana-in-pennsylvania/">key lawmakers</a>, <a href="https://www.spotlightpa.org/news/2025/02/marijuana-cannabis-recreational-legalization-pennsylvania-josh-shapiro-budget-gop-support/">state officials</a> and <a href="https://www.pa.gov/governor/newsroom/2025-press-releases/governor-shapiro-unveils-2025-26-budget-proposal.html">Governor Josh Shapiro</a> all signaling readiness for reform. The renewed push includes a bipartisan effort in the legislature, as well as a public campaign by U.S. Senator <a href="https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/">John Fetterman</a> (D-PA), who is rallying national support for federal legalization.
<h2 class="wp-block-heading">Fetterman's Petition And National Push</h2>
Fetterman, a long-time proponent of cannabis reform, has launched an <a href="https://act.johnfetterman.com/sign/20250222-legal-weed-petition-email">official petition</a> urging federal legalization. His campaign is emphasizing the broad support for the policy and calling for congressional action. In an email blast, his team stated that he is "proud to be fighting for legal weed." The senator has remained outspoken on the issue, saying, "I might be in the Senate, but now we're still struggling and dicking around and we should just make legal weed."
<h2 class="wp-block-heading">State Lawmakers Signal Readiness For Reform</h2>
At the state level, lawmakers from both parties have voiced support for legalization. Senator Sharif Street (D), a long-time advocate, has <a href="https://www.marijuanamoment.net/top-pennsylvania-police-and-health-officials-say-theyre-prepared-to-implement-marijuana-legalization/">expressed</a> confidence that reform will "happen this year." Republican Senator Gene Yaw, once hesitant on the issue, recently <a href="https://www.wkok.com/senator-yaw-compares-marijuana-to-alcohol-and-tobacco/">acknowledged</a> that prohibition has been a failure. "I don't think marijuana is any different than these other things we've regulated and taxed," he said, comparing it to alcohol and tobacco.
<h2 class="wp-block-heading">Agencies Preparing For Legalization</h2>
Beyond legislative support, Pennsylvania's law enforcement and health officials have <a href="https://www.marijuanamoment.net/top-pennsylvania-police-and-health-officials-say-theyre-prepared-to-implement-marijuana-legalization/">indicated</a> they are prepared to implement legalization if lawmakers act. Police and health agencies have signaled their willingness to work with the legislature and the governor's office to craft a regulatory framework.
Governor Shapiro also proposed legalizing adult-use cannabis in his latest budget, <a href="https://www.pa.gov/governor/newsroom/2025-press-releases/governor-shapiro-2025-26-budget-address-as-prepared.html">projecting</a> $1.3 billion in new tax revenue over five years. Shapiro <a href="https://www.spotlightpa.org/news/2025/02/josh-shapiro-pennsylvania-budget-legal-weed/">proposed</a> a 20% wholesale tax on cannabis, which, when combined with other fees and taxes, could result in an effective tax rate closer to 26%, reported <a href="https://www.marijuanamoment.net/bipartisan-pennsylvania-senators-announce-new-marijuana-legalization-plan-criticizing-governors-proposed-cannabis-tax-rate-as-too-high/">Marijuana Moment</a>. This has drawn criticism from lawmakers and industry stakeholders who argue it might push consumers toward the illicit market.
<h2 class="wp-block-heading">The Road Ahead</h2>
With bipartisan backing, agency preparedness and public support growing, Pennsylvania appears closer than ever to joining the list of states that have embraced legal cannabis. The key remaining hurdles will be finalizing a legislative framework, securing enough votes for passage, and negotiating a tax structure that balances state revenue with competitive pricing.
Fetterman's federal push and the state's mounting momentum reflect a larger trend in U.S. cannabis policy, where resistance to legalization is gradually fading. The coming months will be critical in determining whether Pennsylvania can make good on lawmakers' predictions and deliver a regulated cannabis market by year's end.
Lead image via Shutterstock

Cannabis

Government

Legal

Pennsylvania Moves Toward Marijuana Legalization As Fetterman, Shapiro And Others Back Cannabis Reform

CLIR

ClearSign Technologies Receives Purchase Order For Flare For California Project; Final Project Expected To Be Fabricated, Shipped In Q2 2025

GlobalFoundries Collaborates With MIT To Advance Research And Innovation On Essential Chips For AI

Piper Sandler analyst Peter Keith maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Overweight and lowers the price target from $307 to $296.

Piper Sandler Maintains Overweight on Lowe's Companies, Lowers Price Target to $296

Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators
NEW YORK, Feb. 27, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4371739-1&amp;h=843607182&amp;u=https%3A%2F%2Fwww.luciddx.com%2F&amp;a=Lucid+Diagnostics+Inc.">Lucid Diagnostics Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>)&nbsp;("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>), today announced that a consortium of prestigious academic medical centers, led by principal investigators from <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4371739-1&amp;h=1470964318&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4278246-1%26h%3D3737148535%26u%3Dhttps%253A%252F%252Fcase.edu%252F%26a%3DCase%2BWestern%2BReserve%2BUniversity&amp;a=Case+Western+Reserve+University">Case Western Reserve University</a> (CWRU) and University Hospitals (UH), has been awarded an $8 million <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4371739-1&amp;h=1528757052&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4275356-1%26h%3D41289005%26u%3Dhttps%253A%252F%252Fwww.nih.gov%252F%26a%3DNational%2BInstitutes%2Bof%2BHealth&amp;a=National+Institutes+of+Health">National Institutes of Health</a> (NIH) R01 grant to conduct a five-year clinical study designed to evaluate esophageal precancer detection using Lucid's <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4371739-1&amp;h=3163678957&amp;u=https%3A%2F%2Fwww.luciddx.com%2Fprecancer-detection%2Fesocheck&amp;a=EsoCheck%C2%AE+Esophageal+Cell+Collection+Device">EsoCheck&#xAE; Esophageal Cell Collection Device</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4371739-1&amp;h=816772117&amp;u=https%3A%2F%2Fwww.esoguard.com%2F&amp;a=EsoGuard%C2%AE+Esophageal+DNA+Test">EsoGuard&#xAE; Esophageal DNA Test</a>&nbsp; among at-risk individuals without symptoms of chronic gastroesophageal reflux disease (GERD).

Biotech

General

LUCD

PAVM

Lucid Diagnostics Partners With NIH For $8M Study On Esophageal Precancer Detection Using EsoCheck And EsoGuard; 5-Year Clinical Study Involves Case Western Reserve University And University Hospitals

Barclays analyst Andrew Mok maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and lowers the price target from $271 to $249.

Barclays Maintains Overweight on Universal Health Servs, Lowers Price Target to $249

HSAI

Hesai Technology Acquires Swiss Digital Lidar Patents

Needham analyst Tom Nikic reiterates Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) from Hold to Hold.

SHOO

Needham Reiterates Hold on Steven Maddento Hold

Quoin Pharmaceuticals shares are trading higher after the company announced whole body data from ongoing pediatric netherton syndrome study.

FBLG

FibroBiologics And Charles River Complete And Release CYWC628 Master Cell Bank

Press Releases

Bluerock Homes Trust (BHM) Announces Key Dates For 2024 Annual Meeting Of Stockholders

Dividends

Bluerock Homes Trust (BHM) Announces Second Quarter Dividends on Series A Preferred Stock

Bluerock Homes Trust (BHM) Board Declares Increased Dividends and Enhanced Terms for its Series A Preferred Stock

Bluerock Homes Trust (BHM) Announces Third Quarter Dividends on Series A Preferred Stock

Bluerock Homes Trust (BHM) Announces Fourth Quarter Dividends on Series A Preferred Stock

Bluerock Homes Trust (BHM) Announces First Quarter Dividends on Series A Preferred Stock

BHM 2024 Tax Reporting Information For 2024 Dividends

Bluerock Homes Trust (BHM) Announces New Series A Preferred Stock Redemption Safeguard Policy

Comments

Bluerock Homes Trust

Bluerock Homes Trust (BHM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga